Executive Summary The global Non-Small Cell Lung Cancer (NSCLC) market is entering a transformative phase driven by rapid advances in precision oncology, biomarker-guided treatment approaches, next-generation immunotherapies, and expanding molecular diagnostics. Representing approximately 85% of all lung cancer cases, NSCLC remains